Miller M J, Farahmandian I, Arfaa F, Katz N, Winsor E, Bennett E
South Med J. 1978 Feb;71(2):137-40. doi: 10.1097/00007611-197802000-00015.
Levamisole (Decaris, Belgium) was tested in Iran, Brazil, and in Mississippi and Louisiana for its efficacy as a single-dose oral treatment for Ascaris infections. Subjects were children ages 2 to 15 years, and numbers treated with levamisole and comparative anthelmintics are as follows: 453 with levamisole; 461 with piperazine citrate; 17 with pyrantel pamoate; and 19 with a placebo. Cure rates and total reduction in mean egg counts observed were 92% and 98% respectively for levamisole and 66% and 90% for piperazine. Sixteen of 17 treated with pyrantel pamoate were cured. In none of the drugs were there notable side reactions, but in all four studies side effects were more frequent with piperazine than with levamisole. Levamisole was found to be a well-tolerated, highly effective single-dose ascaricide. It should prove to be particularly useful for mass chemotherapy in Ascaris control programs.
左旋咪唑（比利时的驱虫净）在伊朗、巴西以及美国密西西比州和路易斯安那州进行了测试，以检验其作为单剂量口服药物治疗蛔虫感染的疗效。受试者为2至15岁的儿童，接受左旋咪唑及对照驱虫药治疗的人数如下：453人使用左旋咪唑；461人使用枸橼酸哌嗪；17人使用噻嘧啶；19人使用安慰剂。观察到的治愈率和平均虫卵计数的总降低率分别为：左旋咪唑92%和98%，枸橼酸哌嗪66%和90%。17名接受噻嘧啶治疗的患者中有16人治愈。所有药物均未出现明显副作用，但在所有四项研究中，哌嗪的副作用比左旋咪唑更常见。结果发现，左旋咪唑是一种耐受性良好、高效的单剂量杀蛔虫剂。它在蛔虫控制项目的大规模化疗中应会特别有用。
